The Japanese generics giant shared its annual results for 2023 in what was a transformative year for the company that included the sale of a subsidiary and government inspections.
Sawai Pharmaceutical has reported an 8% growth in net sales for its 2023 fiscal year ending 31 March 2024, narrowly missing past forecasts of its annual results for the year.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.
Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
